UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities and Exchange Act of 1934
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 16, 2021
BIOSECURITY TECHNOLOGY, INC.
(Exact Name of Registrant as Specified in its Charter)
Nevada | 333-224157 | 35-2606208 | ||
(State of Other Jurisdiction) | (Commission File Number) | (IRS Employer Identification Number) |
3821 S 148th St Omaha, Nebraska 68144
(Address of principal executive offices, including zip code)
800-494-9604
(Registrant’s telephone number, including area code)
Copies to:
Peter Campitiello, Esq.
McCarter & English, LLP
Two Tower Center Boulevard
East Brunswick, New Jersey 08816
Tel: 732-867-9741
Fax: 732-392-1901
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Merger Act (17 CFR 240.14a -12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Merger Act (17 CFR 240.14d -2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Merger Act (17 CFR 240.13e -4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY NOTE
Biosecurity Technology, Inc. (the “Company”) is filing this Amendment No. 1 to Current Report on Form 8-K (the “Amendment”) to amend its Current Report on Form 8-K (the “Form 8-K”), which was originally filed with the Securities and Exchange Commission on February 26, 2021.
This Amendment amends the Form 8-K to provide, as required by Item 9.01, the unaudited interim financial statements of Biosecurity Technology, LLC, a Wyoming limited liability company (“BST”) and the unaudited pro forma condensed consolidated financial information related to the acquisition of BST, by the Company.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial statements of businesses acquired.
Financial Statements of Biosecurity Technology, LLC, a Wyoming limited liability company, for the years ended December 31, 2020 and 2019
(b) Pro forma financial information.
Unaudited proforma financial statements of the Company and its subsidiaries
(d) Exhibits
1
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 3, 2021 | BIOSECURITY TECHNOLOGY, INC. | |
By: | /s/ Dan Lynn | |
Name: Dan Lynn | ||
Title: Chief Executive Officer |
2